SCHEMBL4677697

SCHEMBL4677697

O=C(O)C(O)=CC(=O)c1csc(S(=O)(=O)c2ccc(F)cc2)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
AKR1C3 P42330 1/20 0.34
HTR2A P28223 4/20 0.34
KCNH2 Q12809 3/20 0.34
PTGS1 P23219 2/20 0.34
MAPT P10636 4/20 0.32
KMT2A Q03164 4/20 0.32
MEN1 O00255 3/20 0.32
ALDH1A1 P00352 3/20 0.32
LMNA P02545 3/20 0.32
HTT P42858 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MITF O75030 1/20 0.32
CASP6 P55212 1/20 0.32
IKBKB O14920 1/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677691 1.00 PTGS2 (0.34) PTGS2AKR1C2AKR1C1AKR1C3HTR2A
SCHEMBL4675097 0.88 ALDH1A1 (0.36) PTGS2PTGS1MAPTKMT2AMEN1
SCHEMBL4675093 0.88 ALDH1A1 (0.36) PTGS2PTGS1MAPTKMT2AMEN1
SCHEMBL4672259 0.88 ALDH1A1 (0.37) PTGS2AKR1C2AKR1C1AKR1C3PTGS1
SCHEMBL4672257 0.88 ALDH1A1 (0.37) PTGS2AKR1C2AKR1C1AKR1C3PTGS1
SCHEMBL4677355 0.79 HTR2A (0.31) HTR2AKCNH2
SCHEMBL4672466 0.79 PTGS1 (0.31) PTGS2PTGS1
SCHEMBL4676699 0.78 HTR2A (0.39) PTGS2AKR1C2AKR1C1AKR1C3HTR2A
SCHEMBL4676696 0.78 HTR2A (0.39) PTGS2AKR1C2AKR1C1AKR1C3HTR2A
SCHEMBL4672592 0.76 PTGS2 (0.38) PTGS2AKR1C2AKR1C1AKR1C3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTGS2 4586/4885AKR1C2 24/4885AKR1C1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.